Rising prevalence of iron deficiency coupled with upsurge in chronic renal disease patients undergoing dialysis are projected to augment the growth of intravenous iron drug market
Free Webex Call
Global intravenous iron drugs market is anticipated to grow at a significant rate in the forecast years, 2024-2028. Rising prevalence of iron deficiency coupled with upsurge in chronic renal disease patients undergoing dialysis are projected to augment the growth of intravenous iron drug market. Anemia is the most common blood disorders which is caused due to the iron deficiency. According to the American Society of Hematology, anemia is one of the most common blood disorders in the United States and has affected over 3 million people in the country. Anemia is highly prevalent in pregnant women and can be harmful to baby. According to the Vitamin and Mineral Nutrition Information System (VMNIS) survey, about 40% of mothers and children in developing nations are anemic. Additionally, rising research and development (R&D) activities in intravenous iron, along with rising government funding for the research is expected to propel the growth of the market.Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The market of global intravenous iron drugs is segmented into application, product, end-user, company and region. The end-use segment is further fragmented into hospitals & clinics, ambulatory care, homecare, and others. Hospitals & clinics is expected to dominate the market in the coming years as they are the major centers for providing intravenous iron drugs to people. Also, the rising number of people suffering from anemia, or iron deficiency is contributing for the growth of the segment.
Based on regional analysis, North America is the dominant region in 2022. This is attributed to the rise in the number of anemic patients over the past years. Also, the lack of iron deficiency due to lifestyle changes, unhealthy eating choices and others are expected to impel the growth of the segment. On the other hand, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period on account of the rising awareness amongst people regarding chronic diseases such as anemia, etc.
Major players operating in the global intravenous iron drugs market include AMAG pharmaceuticals, Inc., Vifor Pharma Group, Daiichi Sankyo Company, Limited, Sanofi SA, Rockwell Medical Inc., Allergan PLC, Pfizer Inc, Nippon Shinyaku Co., Novartis International AG, Takeda Pharmaceutical Company Limited, and Bausch Health Companies Inc.. The companies tend to adopt various organic and inorganic strategies to sustain in the market of intravenous iron drugs.
Objective of the Study:
To analyze and estimate the market size of global intravenous iron drugs market from 2018 to 2021.To estimate and forecast the market size of global intravenous iron drugs market from 2022 to 2028 and growth rate until 2028.
To classify and forecast global intravenous iron drugs market, the market is categorized on the basis of application, product, end-user, company and region.
To identify dominant region or segment in the global intravenous iron drugs market.
To identify drivers and challenges for global intravenous iron drugs market.
To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global intravenous iron drugs market.
To conduct pricing analysis for global intravenous iron drugs market.
To identify and analyze the profile of leading players operating in global intravenous iron drugs market.
To identify key sustainable strategies adopted by market players in global intravenous iron drugs market.
The publisher performed both primary as well as exhaustive secondary research for this study. Initially, The research team sourced a list of manufacturers across the globe. Subsequently, The research team conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, the publisher could include the manufacturers which could not be identified due to the limitations of secondary research. The research team analyzed the manufacturers, distribution channels and presence of all major players across the globe.
The publisher calculated the market size of global intravenous iron drugs market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The research team sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.
Key Target Audience:
- Intravenous iron drugs key players, suppliers, distributors, and other stakeholders
- Government bodies such as regulating authorities and policy makers
- Organizations, forums and alliances related to intravenous iron drugs
Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.Report Scope:
In this report, global intravenous iron drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:Global Intravenous Iron Drugs Market, By Application:
- Intestinal malabsorption syndromes
- Inflammatory diseases
- Gastrectomy/bariatric surgery
- Anemia
- Osier-Weber-Rendu disease
- Angiodysplasia
- Pregnancy
- Others
Global Intravenous Iron Drugs Market, By Product:
- Iron dextran
- Ferric gluconate
- Iron sucrose
- Ferric carboxymaltos
- Iron isomaltoside 100
- Ferumoxytol
Global Intravenous Iron Drugs Market, By End-User:
- Hospitals & Clinics
- Ambulatory Care
- Homecare
- Others
Global Intravenous iron drugs Market, By Region:
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- North America
- United States
- Mexico
- Canada
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in global Intravenous iron drugs market.Available Customizations:
With the given market data, the publisher offers customizations according to a company’s specific needs. The following customization options are available for the report:Company Information
Detailed analysis and profiling of additional market players (up to five).This product will be delivered within 1-3 business days.
Table of Contents
1. Product Overview
2. Research Methodology
3. Executive Summary
5. Global Intravenous Iron Drugs Market Outlook
6. Clinical Trial Analysis
7. Asia-Pacific Intravenous Iron Drugs Market Outlook
8. Europe Intravenous Iron Drugs Market Outlook
9. North America Intravenous Iron Drugs Market Outlook
10. South America Intravenous Iron Drugs Market Outlook
11. Middle East and Africa Intravenous Iron Drugs Market Outlook
12. Market Dynamics
14. Competitive Landscape
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AMAG pharmaceuticals, Inc.
- Vifor Pharma Management Ltd.
- Daiichi Sankyo Company, Limited
- Rockwell Medical Inc.
- Allergan PLC
- Pfizer Inc
- Nippon Shinyaku Co.
- Novartis International AG
- Takeda Pharmaceutical Company Limited
- Bausch Health Companies Inc.
